Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Debio 0123 |
| Synonyms | |
| Therapy Description |
Debio 0123 is an ATP-competitive inhibitor of Wee1 that suppresses CDK1 phosphorylation, which may lead to tumor growth inhibition (Cancer Res 2019;79(13 Suppl):Abstract nr 4423). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Debio 0123 | Debio-0123|Debio0123 | WEE1 Inhibitor 8 | Debio 0123 is an ATP-competitive inhibitor of Wee1 that suppresses CDK1 phosphorylation, which may lead to tumor growth inhibition (Cancer Res 2019;79(13 Suppl):Abstract nr 4423). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05109975 | Phase I | Debio 0123 | A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors | Active, not recruiting | USA | ESP | CHE | 0 |